Literature DB >> 10751237

Gastric acid suppression does not promote clostridial diarrhoea in the elderly.

S Shah1, A Lewis, D Leopold, F Dunstan, K Woodhouse.   

Abstract

Gastric acid prevents bacterial colonization of the stomach and suppression of its secretion might predispose to Clostridium difficile (CD) diarrhoea. We retrospectively studied elderly patients admitted to medical wards of an acute hospital to determine whether the incidence of CD diarrhoea was greater among those previously treated with gastric acid suppressants. From records of stool CD toxin tests undertaken in 1995 and 1996, we found 126 cases with positive results, and selected 126 controls with negative results. Information about pre-morbid illness, predisposing factors for CD and medication received in the preceding 16 weeks was obtained from case-notes. A greater number of CD positive cases had received antibiotics such as Cefuroxime, ciprofloxacin or macrolides with or without metronidazole, were more severely disabled, required assistance for feeding, or had hypoalbuminaemia before the onset of diarrhoea. A greater number of controls had received lactulose, suggesting either that its laxative effect resembled CD infection prompting frequent stool tests, or that it offered protection against CD in this group. Both groups were similar for the use of proton-pump inhibitors or H2-receptor antagonists, suggesting that susceptible elderly patients are not more likely to develop CD diarrhoea after receiving gastric acid suppression therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751237     DOI: 10.1093/qjmed/93.3.175

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  29 in total

1.  Clarification of article on Clostridium difficile--associated colitis.

Authors:  Kenneth Brown
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

Review 2.  Potential adverse effects of proton pump inhibitors.

Authors:  Gregory A Coté; Colin W Howden
Journal:  Curr Gastroenterol Rep       Date:  2008-06

3.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

4.  Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study.

Authors:  Stephanie Linney; Tania Fernandes; Thomas Einarson; Anjana Sengar; John H Walker; Allan Mills
Journal:  Can J Hosp Pharm       Date:  2010-01

Review 5.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

Review 6.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

7.  Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.

Authors:  Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

Review 8.  Clostridioides difficile Infection.

Authors:  Alice Y Guh; Preeta K Kutty
Journal:  Ann Intern Med       Date:  2018-10-02       Impact factor: 25.391

9.  PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics.

Authors:  Alizah Rotramel; Lisa S Poritz; Evangelos Messaris; Arthur Berg; David B Stewart
Journal:  J Gastrointest Surg       Date:  2012-09-25       Impact factor: 3.452

10.  Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

Authors:  Robin L P Jump; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.